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Abstract
Background: Genital warts are important causes of morbidity and their prevalence and incidence can be used to
evaluate the impact of HPV vaccination in a population.
Methods: We enrolled 1020 women in a prospective cohort study in Nigeria and followed them for a mean (SD) of
9 (4) months. Nurses conducted pelvic examinations and collected ectocervical samples for HPV testing. We used
exact logistic regression models to identify risk factors for genital warts.
Results: The mean age of study participants was 38 years, 56% (535/962) were HIV-negative and 44% (427/962)
were HIV-positive. Prevalence of genital warts at enrolment was 1% (4/535) among HIV-negative women, and 5%
(23/427) among HIV-positive women. Of 614 women (307 HIV negative and 307 HIV positive women) for whom we
could compute genital wart incidence, it was 515 (95% CI:13–2872) per 100,000 person-years in HIV-negative and
1370 (95% CI:283–4033) per 100,000 person-years in HIV-positive women. HIV was associated with higher risk of
prevalent genital warts (OR:7.14, 95% CI:2.41–28.7, p < 0.001) while higher number of sex partners in the past year
was associated with increased risk of incident genital warts (OR:2.86, 95% CI:1.04–6.47. p = 0.04). HPV11 was the only
HPV associated with prevalent genital warts in this population (OR:8.21, 95% CI:2.47–27.3, p = 0.001).
Conclusion: Genital warts are common in Nigeria and our results provide important parameters for monitoring the
impact of future HPV vaccination programs in the country. HIV infection and number of sexual partners in past year
were important risk factors for prevalent and incident genital warts respectively.
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Introduction
Genital warts are common manifestations of genital Hu-
man Papillomavirus (HPV) infections [1]. They are com-
monly associated with HPV6 and HPV11 [2]. However,
many other HPV types have also been isolated in genital
warts, including HPV 2, 40, 42, 43 and 54 [3, 4]. Although
there is rising prevalence and incidence of genital warts in
the general population in Europe and the United States,
countries such as Australia and England with high HPV
vaccination coverage have reported a decline in the burden
of genital warts among young women [1, 5–8]. In contrast,
little is known about genital warts in Sub-Saharan Africa
(SSA) [9]. Most studies on genital warts in SSA have been
conducted in high risk populations such as people attend-
ing sexually transmitted diseases’ (STD) clinics or commer-
cial sex workers [9]. Other studies were conducted among
women receiving antenatal care [9].
Genital warts can present with four morphologic fea-
tures – condylomata acuminata, smooth or flat papular le-
sions, or keratotic warts. Apart from their appearance,
they are often symptomless except in some cases of vulvar
warts which may cause dyspareunia and discomfort; penile
warts and pruritus; vaginal warts and vaginal discharge,
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bleeding, obstruction of the birth canal, and neonatal in-
fection which may lead to juvenile onset recurrent papillo-
matosis; perianal and intra-anal warts that cause pain,
bleeding on defecation and pruritus [10–14]. Genital warts
can have profound effects on patients’ quality of life [15].
They may regress spontaneously or remain quiescent for
extended periods. They can be refractory to treatment
with high recurrence rates leading to substantial health
care costs [16]. In 2004, the estimated economic burden
of genital warts exceeded $220 million in the US, [17] and
$64 million in Spain [18]. Data on economic costs are not
available for SSA countries.
Studies show that vaccination with the quadrivalent and
nonavalent HPV vaccine, which offers protection against
HPV 6 and 11, can reduce the incidence of genital warts
[19]. This has renewed interest in estimating and monitoring
the burden of anogenital warts as an early indicator of the
impact of HPV vaccination programs. In Nigeria, there are
isolated, small-sized, pilot HPV vaccination projects but no
systematic, national or regional programs [20]. Therefore,
estimating the pre-vaccination burden of genital warts
would be of practical utility for future monitoring and evalu-
ation projects.
In this study, we describe the prevalence, incidence,
associated risk factors and cervical HPV types associated
with genital warts in Nigerian women.
Methods
Study population
We conducted cervical cancer awareness meetings in town
halls, HIV outpatient clinics, general outpatient and gynae-
cology outpatient clinics in two hospitals (National Hos-
pital, Abuja and University of Abuja Teaching Hospital) in
Abuja, Nigeria. We invited 1300 women to participate in
cervical cancer screening programs at these two hospitals
and enrolled 1020 (78%) women into a prospective cohort
to investigate the prevalence and incidence, host and viral
determinants of persistent HPV infection in HIV negative
and HIV positive women in Nigeria between 2012 and
2013. This study population has been previously described
[21, 22]. We included women over 18 years old with prior
history of penetrative vaginal intercourse and excluded
women who were pregnant, had previous hysterectomies,
had previous history of cervical cancer or its precursor le-
sions or were unable to attend follow up visits.
Trained nurses administered questionnaires to collect in-
formation on participants’ sociodemographic and lifestyle
characteristics. Nine nurses (five at the National Hospital
Abuja and four at the University of Abuja Teaching Hospital)
performed physical and gynecologic examinations on partici-
pants and collected ecto-cervical cell scrapings for HPV de-
termination. All nurses had at least two years of experience
in cervical cancer screening, with at least a Bachelor’s degree
in nursing. All participants were scheduled to return six
months after enrollment, when the baseline procedures were
repeated. Participants were compensated for travel costs and
time. We ascertained HIV status from participant’s self re-
port of a previous test and those without a history of HIV
testing were referred to a counselling and testing center.
HPV DNA detection
We used the SPF10LiPA25 system version 1 for HPV DNA
detection [23]. The LiPA assay can identify 25 high-risk and
low-risk HPV types. Specimens that were positive for HPV
DNA, but did not hybridize with any of the probes in LiPA25
were labeled as HPV undetermined (HPV U).
Genital warts identification
Nurses identified the presence of genital warts by direct vis-
ual inspection with bright light and magnification. We used
the ICD-10-CM Diagnosis Code A63.0 to define genital
warts and included lesions on the labia, vagina, cervix, outer
pubic and anal areas. Prevalent cases were identified at enrol-
ment. Incident cases were identified at follow-up in women
without any visible genital warts at enrolment and no prior
history of self-reported genital warts.
Statistical analysis
We compared the baseline characteristics of HIV positive
and HIV negative women using t-tests for continuous vari-
ables and Fisher’s exact tests for categorical variables. We
used exact logistic regression models to investigate potential
risk factors associated with prevalent and incident genital
warts. Potential risk factors evaluated included sociodemo-
graphic (age, education, socioeconomic status, marital sta-
tus); sexual and vaginal practices (HIV status, condom use,
sexual debut age, lifetime number of partners, number of
partners in past year, douching practice) and body mass
index. All variables were updated at the six month visit and
the updated data was used for incident warts analysis. All
risk factors with p≤ 0.20 in age adjusted models were in-
cluded in multivariable models. We used HIV and age ad-
justed Poisson regression models, with each HPV type
modelled as a binary variable, to evaluate the association be-
tween each HPV type and prevalent genital warts.
To minimize bias in incidence estimates, we used mul-
tiple imputation methods to impute the missing informa-
tion on person time at risk using STATA mi impute regress
module [24]. All analysis of incident genital warts was
based on the imputed data were conducted using Stata ver-
sion 15 (StataCorp LP, College Station, Texas).
Ethical approval
Ethical approval was obtained from the National Health Re-
search Ethics Committee of Nigeria (NHREC/01/01/2007–
01/08/2016) and the University of Maryland Institutional Re-
view Board (HCR-HP-00051495-2). All participants provided
written informed consent.
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Results
Of the 1020 women enrolled, 58 were excluded due to
missing HIV and HPV data (41 missing HIV results, 13
missing baseline HPV results, 4 missing both HIV and
HPV) results leaving 962 women available for prevalent
genital warts analyses. Most participants (72%, 692/962)
completed follow-up visits. Of these 692 women, we ex-
cluded 62 participants whose HPV results were missing at
follow-up leaving 630 women for genital wart incidence
analysis. Sixteen of these women had prevalent genital
warts at the enrolment visit. Therefore, they were no longer
at risk for incident genital warts and were subsequently ex-
cluded leaving 614 women. Among these 614 women, we
imputed person time at risk for 4% (22/614) of participants
who were missing follow-up visit date. All instances of
missing data were in women without incident genital warts.
Sensitivity analysis, comparing results from models with
and without imputed data did not show any significant dif-
ferences. We present results from models with the imputed
data in order to reduce loss of information that would arise
from listwise deletion of cases.
Characteristics of study population
Almost half of the women (44%, 427/962) were HIV posi-
tive (Table 1). Mean age (SD) at enrolment was 38 (8)
years and at sexual debut was 20 (4) years. Most partici-
pants obtained more than six years of formal education
(89%, 858/962) and were married (67%, 647/962). Preva-
lence of smoking (1%, 13/962) and use of oral contracep-
tives (10%, 93/962) were low. Only a third (33%, 303/962)
of the women were neither overweight nor obese. Mean
(SD) follow-up time was 9 (4) months. None of the partic-
ipants had been previously vaccinated for HPV or received
treatment for genital warts.
There was no significant difference among the HIV nega-
tive and HIV positive women with respect to the number
of sexual partners in past year, smoking history, alcohol
consumption, vaginal pH, and previous history of vaginal
infections. More HIV positive women resided in rural envi-
ronments, had low socioeconomic status, were less edu-
cated, more likely to be widowed and more likely to report
condom use compared to HIV negative women (Table 1).
The distribution of low-risk and high-risk HPV types in this
population has been previously described [22].
Factors associated with prevalent and incident genital
warts
In univariate analysis, age, socioeconomic status, HIV sta-
tus, condom use and BMI were associated with prevalent
genital warts, while number of sex partners in the past year
was associated with incident genital warts (Table 2). In a
multivariable model adjusted for age, HIV infection was as-
sociated with a higher risk of prevalent genital warts (OR:
7.14, 95% CI: 2.41–28.7. p < 0.0001) while higher number of
sex partners in the past year was associated with an in-
creased risk of incident genital warts (OR: 2.86, 95% CI:
1.04–6.47. p = 0.04).
Prevalence of genital warts was low below 20 years but
rose rapidly to peak at 20–29 years followed by a decline
till about 40 years when there was a second but smaller
peak (Fig. 1). In a multivariable model adjusted for HIV
and age, HPV11 was the only HPV type significantly asso-
ciated with prevalent genital warts (OR: 8.21, 95% CI:
2.47–27.3. p = 0.001) (Fig. 2). HPV6 was not significantly
associated with prevalent genital warts (OR: 2.21, 95% CI:
0.33–14.8. p = 0.42). Due to the reported association be-
tween HPV6 and genital warts, we included both HPV6
and HPV11 in a multivariable model adjusted for age and
HIV. The results remained largely unchanged for both
HPV11 and HPV6.
Genital warts in HIV negative women
Of the 962 women enrolled, 535 were HIV negative. Among
these HIV negative women, the prevalence of genital warts
at enrolment was 1% (4/535). Two of these women (50%, 2/
4) were positive for any HPV. The HPV types detected were
HPV11 (25%, 1/4) and HPV18 (25%, 1/4) (Table 3). Some
57% (307/535) of these women returned for follow-up and
had complete data for incident genital warts analysis. Only
one of them developed incident genital warts during the
follow-up period. The total person time at risk for genital
warts for HIV negative women was 194 person-years, result-
ing in an incidence rate of 515 cases (95% CI: 13–2872) per
100,000 person-years. Cervical HPV was not detected in this
woman, either at enrolment or during follow-up eight
months later.
Genital warts in HIV positive women
Of the 962 women enrolled, 427 were HIV positive. Preva-
lence of genital warts among these HIV positive women at
enrolment was 5% (23/427). Among those with prevalent
genital warts, 57% (13/23) had single HPV infections, 35%
(8/23) had multiple HPV infections ranging from two to five
types and 8% (2/23) did not have any HPV infections (Table
3). The most prevalent low-risk HPV types detected in these
HIV positive women with genital warts were HPV11 (13%,
3/23) and HPV66 (13%, 3/23). While, the most prevalent
high-risk types were HPV18 (13%, 3/23), HPV51(13%, 3/23),
HPV52 (13%, 3/23) and HPV58 (13%, 3/23) (Table 3).
Some 72% (307/427) of HIV positive women returned for
follow-up. There were three incident cases of genital warts
in these women during 219 person-years of follow-up,
resulting in an incidence rate of 1370 cases (95% CI: 283–
4033) per 100,000 person-years. The HPV types detected at
follow-up in these three women were HPV 35 and HPV 52
in one woman, and none in the other two women. At en-
rolment, all three women had multiple HPV types.
There were three HPV types in two of the women
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(HPV 11, HPV 54, HPV 68 in one woman and HPV
35, HPV 52, HPV 54 in the second woman) and four
HPV types (HPV 44, HPV 53, HPV 58, HPV 66) in
one of the women.
Discussion
We identified HIV infection as a risk factor for prevalent
genital warts and higher number of sex partners in the
past year as a risk factor for incident genital warts in
Table 1 Characteristics of study participants by HIV status at enrolment
Total (N = 962) HIV negative (N = 535) HIV positive (N = 427) p-value
Sociodemographic characteristics
Age, years (Mean, SD) 37.9 (7.72) 38.4 (7.90) 37.2 (7.42) 0.02
Nature of residence (N, %) < 0.001
Urban 431 (45.0) 283 (53.1) 148 (34.9)
Semirural 367 (38.4) 180 (33.8) 187 (44.1)
Rural 159 (16.6) 70 (13.1) 89 (30.0)
Socioeconomic status (N, %) < 0.001
Low 375 (39.0) 152 (28.4) 223 (52.2)
Middle 384 (39.9) 226 (42.2) 158 (37.0)
High 203 (21.1) 157 (29.4) 46 (10.8)
Education (N, %) < 0.001
≤ 6 years 104 (10.8) 45 (8.40) 59 (13.8)
7–12 years 602 (62.7) 294 (55.1) 308 (72.3)
> 12 years 254 (26.5) 195 (36.5) 59 (13.9)
Marital status (N, %) < 0.001
Married 647 (67.3) 421 (78.7) 226 (52.9)
Not married 315 (32.7) 114 (21.3) 201 (47.1)
Lifestyle characteristics
Age at sexual debut, years (Mean, SD) 20.1 (4.04) 20.8 (4.24) 19.2 (3.59) < 0.001
Lifetime number of partners (Mean, SD) 3.43 (3.34) 2.85 (2.35) 4.16 (4.16) < 0.001
Number of partners in preceding year (Mean, SD) 1.00 (0.47) 1.00 (0.34) 1.00 (0.60) 0.86
Ever smokeda (N, %) 13 (1.35) 4 (0.75) 9 (2.11) 0.09
Alcohol Consumptionb (N, %) 129 (13.5) 70 (13.2) 59 (13.9) 0.78
Ever douche (N, %) 606 (63.1) 319 (59.6) 287 (67.4) 0.02
Regularly douche in last 3 months (N, %) 544 (56.5) 284 (53.1) 260 (60.9) 0.32
Condom use (N, %) 290 (30.2) 102 (19.1) 188 (44.0) < 0.001
Oral contraceptive use (N, %) 93 (9.67) 38 (8.90) 55 (10.3) 0.51
Clinical characteristics
Body Mass Index, kg/m2 (N, %) < 0.001
Normal weight, 18.5–24.9 303 (33.4) 136 (26.6) 167 (42.0)
Overweight, 25.0–29.9 324 (35.6) 184 (35.9) 140 (35.3)
Obese, ≥ 30.0 282 (31.0) 192 (37.5) 90 (22.7)
Vaginal pH (N, %) 0.21
< 4.5 73 (7.59) 47 (8.79) 26 (6.09)
4.5–5.5 68 (7.07) 34 (6.36) 34 (7.96)
> 5.5 821 (85.3) 454 (84.9) 367 (85.9)
Diagnosis of vaginal infection in last 3 monthsc (N, %) 23 (2.39) 17 (3.18) 6 (1.41) 0.09
Currently on antiretroviral therapy (N, %) – – 395 (92.5)
a Ever smoked up to 100 cigarrette sticks in lifetime
b Consumption of at least one unit of alcohol every three months
c Infections include bacterial vaginosis, Candidiasis, Trichomonas, Herpes, Chlamydia, Pelvic inflammatory disease, gonorrhoea, syphilis and genital warts
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this study. Cervical HPV11, but not HPV6 infection was
associated with prevalent genital warts.
Previous studies have shown that HIV positive women
are more likely to be infected with HPV, have multiple
HPV infections, [25] and have slower clearance com-
pared with HIV negative women [26]. Clearance of HPV
infection is mediated by a cell-mediated immune re-
sponse, and the cellular response against genital warts
includes an antigen specific CD4+ Th1 response [27].
Therefore, the increased risk of genital warts in HIV
positive women is likely due to the reduced ability of the
immune system to control HPV infections, as well the
shared risk factors for transmission of HIV and HPV
infections.
Given the ubiquity of HPV infections, the number of sex-
ual partners in the past year is a corollary of exposure to
new HPV infections from new sexual partners. Women
with a higher number of sexual partners in the preceding
year are more likely to have been exposed to new HPV in-
fections from new sexual partners than women who report
fewer number of sexual partners [28]. Genital warts have a
short incubation period, with about 65% of people exposed
to partners with genital warts, developing lesions within
1–8 months [29]. Therefore, the three-fold increased
risk of incident genital warts with each additional new
partner in the preceding year observed in our study
likely reflects the clinical manifestations of newly ac-
quired HPV infections.
Table 2 Association between participant sociodemographic, potential risk factors and genital warts
Variable Prevalent genital warts Incident genital warts
Total N = 962 n (%) Odds Ratio (95% CI) p Total N = 614 n (%) Odds Ratio (95% CI) p
Age 0.94 (0.88–0.99) 0.01 0.92 (0.80–1.06) 0.28
Education, years completed
≤ 6 years 104 5 (5) Reference (1.00) 70 0 (0) Reference (1.00)
7–12 602 15 (3) 0.51 (0.17–1.82) 0.32 382 3 (1) 0.73 (0.08 – Inf) 1.00
> 12 254 7 (3) 0.56 (0.15–2.30) 0.50 160 1 (1) 0.45 (0.01 – Inf) 1.00
Socio-economic status
Low 375 15 (4) Reference (1.00) 238 3 (1) Reference (1.00)
Middle 384 11 (3) 0.71 (0.30–1.68) 0.51 251 1 (0) 0.32 (0.01–3.98) 0.59
High 203 1 (0) 0.12 (0.00–0.78) 0.02 125 0 (0) 0.51 (0.00–4.78) 0.58
Marital status
Married 647 15 (2) Reference (1.00) 405 2 (0) Reference (1.00)
Not married 315 12 (4) 1.67 (0.70–3.87) 0.27 209 2 (1) 1.95 (0.14–27.1) 0.84
Douche
No 355 8 (2) Reference (1.00) 218 1 (0) Reference (1.00)
Yes 606 19 (3) 1.40 (0.58–3.74) 0.56 395 3 (1) 1.64 (0.13–86.5) 1.00
HIV status
No 535 4 (1) Reference (1.00) 307 1 (0) Reference (1.00)
Yes 427 23(5) 7.54 (2.54–30.2) < 0.001 307 3 (1) 2.90 (0.23–153) 0.65
Condom use
No 672 13 (2) Reference (1.00) 433 2 (0) Reference (1.00)
Yes 290 14 (5) 2. 57 (1.10–6.02) 0.03 181 2 (1) 2.32 (0.17–32.3) 0.70
Age at sexual initiation 0.97 (0.88–1.07) 0.56 0.87 (0.64–1.15) 0.39
Per partner increase in total lifetime
sex partners
1.05 (0.96–1.13) 0.23 1.04 (0.77–1.20) 0.52
Per partner increase in total sex
partners in past year
1.18 (0.49–2.37) 0.75 3.16 (1.20–6.99) 0.02
Body Mass Index, Kg/m2
Normal weight 303 12 (4) Reference (1.00) 187 1 (1) Reference (1.00)
Overweight 324 6 (2) 0.46 (0.14–1.34) 0.18 214 1 (0) 0.90 (0.01–70.9) 1.00
Obese, ≥ 30 282 7 (2) 0.62 (0.20–1.73) 0.44 178 1 (1) 1.07 (0.01–84.1) 1.00
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Prevalence of HPV6 was 4% (1/27) in women with geni-
tal warts compared to the overall prevalence of 1% (10/
962) in the study population, while prevalence of HPV11
was 15% (4/27) in women with genital warts compared to
the overall prevalence of 2% (15/962) in the study popula-
tion [22]. In age adjusted models, HPV11, but not HPV6,
was significantly associated with prevalent genital warts.
The prevalence of cervical HPV6 infection among women
with prevalent genital warts in our study are lower than that
from other studies in Burkina Faso (6%) [30], South Africa
(5%) [30], Germany (67%) [31], United States (17%) [4], and
England (33%) [32]. These differences may reflect the relative
contributions of non-HPV 6/11 infections to the burden of
genital warts, and differences in the age distribution of the
study populations. Due to the recurring nature of genital
wart infections and the transient nature of most cervical
HPV infections, inferences based on HPV detection at time
of genital wart diagnosis need to be interpreted with caution.
Intermittent detection of persistent HPV infection may be
due to episodic fluctuation in viral load levels including
Fig. 1 Point prevalence of genital warts at enrolment by HIV status and age
Fig. 2 Association between cervical type-specific low-risk and high-risk HPV and prevalent genital warts, adjusted for age and HIV status
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below the detection limit of many HPV DNA assays [33].
HPV infections may also go through a phase of latency in
the basal cells of the cervical epithelium during which period
the virus may be undetectable [3].
The prevalence of genital warts among HIV negative
women in our study is lower than that found in HIV nega-
tive, pregnant women in Malawi where prevalence was ap-
proximately 2% [9]. This is consistent with results from
previous studies which show that HPV prevalence tend to
be higher among pregnant compared to age-matched non
pregnant women as a result of temporary immunosup-
pression and increased steroid hormones during preg-
nancy [34]. The prevalence of genital warts in HIV
positive women in our study is similar to that in a recent
study of HIV positive women in South Africa (6%) but
slightly lower than that in Burkina Faso (8%) [30]. Geo-
graphic variations in any HPV prevalence, cultural envir-
onment, sexual behavior, HPV viral characteristics and
host susceptibility may explain these findings. In a
meta-analysis assessing the burden of any HPV infection
in women with normal cytological findings, standardized
by country specific population sizes, any HPV prevalence
was higher in Eastern Africa (34%) compared to Western
Africa, which includes Nigeria (20%) [35]. Similarly, the
incidence and prevalence of other HPV associated diseases
such as cervical cancer is higher in Eastern Africa com-
pared to Western Africa [35].
We observed a peak prevalence of genital warts in
women aged 20–29 years followed by a decline till about
40–49 years old where there was a second but smaller peak.
Table 3 Cervical HPV type distribution in 27 women with prevalent genital warts at enrolment by HIV status
Cervical HPV type Prevalent genital warts
Total (n = 27) * HIV- (n = 4) HIV + (n = 23)
Number infected (%) Number infected (%) Number infected (%)
Low risk HPV
HPV 6 1 (4) 0 (0) 1 (4)
HPV 11 4 (15) 1 (25) 3 (13)
HPV 43 1(4) 0 (0) 1 (4)
HPV 44 2 (7) 0 (0) 2 (9)
HPV 53 1 (4) 0 (0) 1 (4)
HPV 66 3 (11) 0 (0) 3 (13)
HPV 70 1 (4) 0 (0) 1 (4)
HPV 74 1 (4) 0 (0) 1 (4)
HPV U 1 (4) 0 (0) 1 (4)
High risk HPV
HPV 16 1 (4) 0 (0) 1 (4)
HPV 18 4 (15) 1 (25) 3 (13)
HPV 31 1 (4) 0 (0) 1 (4)
HPV 33 1 (4) 0 (0) 1 (4)
HPV 35 2 (7) 0 (0) 2 (9)
HPV 45 1 (4) 0 (0) 1 (4)
HPV 51 3 (11) 0 (0) 3 (13)
HPV 52 3 (11) 0 (0) 3 (13)
HPV 56 2 (7) 0 (0) 2 (9)
HPV 58 3 (11) 0 (0) 3 (13)
Any HPV infection 23 (85) 2 (50) 21 (91)
Single HPV infection 15 (56) 2 (50) 13 (57)
Multiple HPV infection
2 types 3 (11) 0 (0) 3 (13)
3 types 1 (4) 0 (0) 1 (4)
4 types 3 (11) 0 (0) 3 (13)
5 types 1 (4) 0 (0) 1 (4)
*Numbers add up to > 27 because some women (8/27) had multiple infections ranging from two to five HPV types
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This result is consistent with our previous findings on
prevalent low risk HPV infection in this study population
and the epidemiology of several other STIs from other pop-
ulations where the highest peaks are observed in young
people soon after sexual debut, with a secondary peak in
middle age in some populations [22, 36]. Possible explana-
tions for the bimodal pattern include the reactivation of la-
tent HPV infections in later life due to waning of
immunity, acquisition of new HPV infections due to new
sexual partners and possibly cohort effects [37].
The incidence rates of 515 in HIV negative and 1370
per 100,000 person-years in HIV positive women in our
study are higher than that from European and North
American studies [5]. In a systematic review of popula-
tion based incidence rates using data from medical chart
reviews and retrospective administrative databases in
European and North American populations, Patel et al.
reported incidence rates of genital warts per 100,000
person-years ranging from 76 in Germany to 430 in Italy
[5]. Incidence of genital warts based on clinical pelvic
examinations tend to be higher than that obtained from
medical chart reviews or administrative databases be-
cause patients may be unwilling or unable to present to
health care facilities [5]. Additionally, medical records
and administrative databases may be incomplete and the
quality of information provided by different health care
workers may vary significantly.
Few studies of the incidence of genital warts have been
conducted in SSA and these have been in high risk pop-
ulations such as HIV negative commercial sex workers
in Burkina Faso where the incidence was 1100 per
100,000 person-years, [9] and in women younger than
40 years, attending an STD clinic in Nigeria with inci-
dence of 2700 per 100,000 person-years [9]. A recent
study found genital wart incident rates of 2470 and 2330
per 100,000 person years in HIV positive women in Bur-
kina Faso and South Africa respectively [30]. These rates
are higher than what we observed in HIV positive
women in our study. Factors related to differences be-
tween the study populations and differences in HIV
epidemiology may account for these findings.
We found that women younger than 30 years old or
HIV negative were more likely to be lost to follow up in
our study. Considering that the prevalence of genital
warts was higher in women less than 30 years old in this
study, it is possible we underestimated the incidence
of genital warts as a result. As incidence estimates
were stratified by HIV status, the increased likelihood
of being lost to follow up among HIV negative women,
is more likely to influence estimates for HIV negative
but not HIV positive women. We previously published
a detailed study of predictors of attrition in this cohort
and identified age and HIV status as important risk
factors [38].
We found that HIV positive women were significantly
more likely to report condom use than HIV negative
women. This finding may reflect recent efforts by the
President’s Emergency Plan for AIDS Relief (PEPFAR) pro-
gram to promote condom use among sexually active HIV
positive individuals to reduce risk of HIV and other sexu-
ally transmitted infections (STI) [39]. It is plausible that
there are differences in the psychological and recall pro-
cesses for self reported sexual history among HIV negative
and HIV positive women. HIV positive women may feel a
sense of personal responsibility in preventing the trans-
mission of HIV and other STIs to sexual partners and
therefore may over report condom use, which they may
perceive as a more socially desirable response. This is sup-
ported by our previous study showing less reliability in
reporting sexual behaviour among HIV positive compared
to HIV negative women in this study population [21].
To our knowledge, this is the first longitudinal study
to describe the prevalence and incidence of genital warts
among HIV negative and HIV positive women who are
neither pregnant nor considered to be at increased risk
for other STDs in West Africa. Due to the recurring na-
ture of genital warts, newly detected cases of genital
warts may truly be incident cases or may be recurrent
episodes. In our study, we collected self-reported history
of previous genital warts and excluded these cases from
incidence analyses. However, it is possible that there
may be some residual confounding as a result of inac-
curacies in the self-reported history.
HPV detection was based on cells obtained from the
cervix which may not be representative of the causative
HPV types in the genital warts. Previous studies have re-
ported varying degrees of type specific concordance be-
tween cervical HPV and HPV isolated from genital warts
[4, 31]. In these studies, agreements for HPV6 detected in
genital swabs and cervical swabs among young women
with genital warts ranged from 16% in a US study, [4] to
71% in a German study [31]. Therefore, it is likely that the
prevalence estimates of HPV types in our study underesti-
mate the true prevalence of the different HPV types in
genital warts. Despite this limitation, our results provide
some information on the HPV type distribution among
Nigerian women with genital warts. Further studies, that
directly sample gential warts are needed to better under-
stand genital warts epidemiology in Nigeria.
Other limitations of our study include small sample size,
the small number of incident genital warts despite the rela-
tively large follow-up person time and the absence of HIV
parameters such as viral load and CD4+ count. Therefore,
our effect estimates for incident genital warts may be un-
stable. In our study design, we purposively enroled HIV
negative and HIV positive women. Therefore, the preva-
lence of HIV in our study population does not represent
HIV prevalence in the Nigerian female population. Hence,
Dareng et al. BMC Infectious Diseases           (2019) 19:27 Page 8 of 10
we provide prevalence and incidence estimates separately
for HIV negative and HIV positive populations.
Genital warts diagnosis in our study was based on visual
identification with bright light. Without histological con-
firmation, it is possible that some other genital conditions
such as seborrheic keratoses, dysplastic and benign nevi,
molluscum contagiosum and neoplastic lesions may have
been misclassified as genital warts [13]. However, biopsy is
not routinely recommended for genital warts diagnosis, and
the nurses in our study were trained to rule out these other
genital conditions and refer lesions suspicious of neoplasia.
Conclusion
Our study provides important information on the epidemi-
ology of genital warts among women in Nigeria. The results
can be used for monitoring and modelling effectiveness of
the public health impact of future HPV vaccination pro-
grams in Nigeria. Our findings of a high burden of genital
warts and the association between cervical HPV11 and geni-
tal warts support the use of either the quadrivalent or nona-
valent vaccine for genital wart prevention in future HPV
vaccination programs in Nigeria.
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